| Drug ID: | Drug148 |
|---|---|
| Drug Name: | Upadacitinib |
| CID: | 58557659 |
| DrugBank ID: | DB15091 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT06780683, , NCT06274996, , NCT05782907, , NCT06095596, , NCT03653026, , NCT02819635, , NCT03345836, , NCT05867329 |
| Molecular Formula: | C17H19F3N6O |
| Molecular Weight: | 380.4 g/mol |
| Isomeric SMILES: | CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F |
| Synonyms: | Upadacitinib; ABT-494; Rinvoq; Upadacitinib anhydrous; UNII-4RA0KN46E0; 4RA0KN46E0; ABT 494; ABBV-599 COMPONENT UPADACITINIB; 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-; REL-(-)-(3S,4R)-3-ETHYL-4-(3H-IMIDAZO(1,2-A)PYRROLO(2,3-E)PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE |
| Phase 0: | 1 |
| Phase 1: | 6 |
| Phase 2: | 17 |
| Phase 3: | 49 |
| Phase 4: | 10 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1172 | 58557659 | Upadacitinib | 3718 | JAK3 | Homo sapiens (human) | None | |
| dt1173 | 58557659 | Upadacitinib | 3718 | JAK3 | Homo sapiens (human) | Inhibitor | |
| dt1174 | 58557659 | Upadacitinib | 3716 | JAK1 | Homo sapiens (human) | Inhibition | |
| dt1175 | 58557659 | Upadacitinib | 3717 | JAK2 | Homo sapiens (human) | Inhibition | |
| dt1176 | 58557659 | Upadacitinib | 3718 | JAK3 | Homo sapiens (human) | Inhibition | |
| dt1177 | 58557659 | Upadacitinib | 7297 | TYK2 | Homo sapiens (human) | Inhibitor | |
| dt1178 | 58557659 | Upadacitinib | 1565 | CYP2D6 | Homo sapiens (human) | None | |
| dt1179 | 58557659 | Upadacitinib | 3716 | JAK1 | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06780683 | Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease | None | RECRUITING | Xiang Gao | Inflammatory Bowel Disease|Crohn's Disease|Ulcera… | DRUG: Upadacitinib | Details |
| NCT06660693 | Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis | PHASE3 | NOT_YET_RECRUITING | McMaster University | Colitis, Ulcerative | DRUG: Upadacitinib Oral Product | Details |
| NCT03653026 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis | PHASE3 | COMPLETED | AbbVie | Ulcerative Colitis (UC) | DRUG: Placebo|DRUG: Upadacitinib | Details |
| NCT03006068 | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | PHASE3 | ACTIVE_NOT_RECRUITING | AbbVie | Ulcerative Colitis (UC) | DRUG: Upadacitinib (ABT-494)|DRUG: Placebo | Details |
| NCT02819635 | A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) | PHASE2|PHASE3 | COMPLETED | AbbVie | Ulcerative Colitis (UC) | DRUG: Placebo|DRUG: Upadacitinib | Details |
| NCT03345836 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy | PHASE3 | COMPLETED | AbbVie | Crohn's Disease | DRUG: Matching Placebo for Upadacitinib|DRUG: Upa… | Details |
| NCT06922331 | Age-Stratified Efficacy of Upadacitinib in Refractory Inflammatory Bowel Disease Among Asian Populations: Pediatric Crohn's Disease Versus Elderly Ulcerative Colitis Cohort Analysis | Not Available | Not recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn's Disease (CD);Ulcerative Colitis (UC);… | Drug: Upadacitinib | Details |
| ChiCTR2500098001 | A comparative study on the efficacy and safety of upadacitinib versus various biologic agents in patients with inflammatory bowel disease | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University | Inflammatory bowel disease, including ulcerative … | Observation group:None; | Details |
| ChiCTR2400090481 | A real-world safety study of upadacitinib in Chinese patients with inflammatory bowel disease | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Inflammatory bowel disease | CD patients:No intervention;UC patients:No interv… | Details |
| ChiCTR2400085646 | A survey of Chinese physicians' preference and clinical use of Upadacitinib | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Inflammatory bowel disease | Physicians:No intervention; | Details |
| ChiCTR2300075317 | A prospective study on effectiveness, safety, lifestyle behavior, and treatment preferences of upadacitinib in patients with inflammatory bowel disease | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Inflammatory bowel disease | Case series:No intervention; | Details |
| NCT06274996 | Efficacy and Safety Analysis of Upadacitinib in Inflammatory Bowel Disease | None | COMPLETED | Sixth Affiliated Hospital, Sun Yat-sen University | Inflammatory Bowel Diseases | DRUG: Upadacitinib | Details |
| NCT05494606 | An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice | None | ACTIVE_NOT_RECRUITING | AbbVie | Ulcerative Colitis | None | Details |
| NCT06581042 | Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium | None | RECRUITING | AbbVie | Ulcerative Colitis|Crohn's Disease | None | Details |
| NCT05867329 | A Trial for Acute Severe Ulcerative Colitis | PHASE4 | RECRUITING | Berinstein, Jeffrey | Ulcerative Colitis Acute | DRUG: Cyclosporine Injection (IV)|DRUG: Cyclospor… | Details |
| NCT05496348 | Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis | None | RECRUITING | AbbVie | Ulcerative Colitis | None | Details |
| NCT05782907 | Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis. | PHASE3 | RECRUITING | AbbVie | Ulcerative Colitis | DRUG: Upadacitinib | Details |
| NCT06838845 | An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC) | None | NOT_YET_RECRUITING | AbbVie | Ulcerative Colitis | None | Details |
| NCT06095596 | Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis | None | RECRUITING | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn Disease | DRUG: Upadacitinib|DRUG: Vedolizumab | Details |
| NCT06459297 | Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease | None | RECRUITING | AbbVie | Ulcerative Colitis|Crohn's Disease | None | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Cost-Effectiveness Analysis of Upadacitinib in Patients With Moderately to Seve…
PMID: 39954537
Year: 2025
Relationship Type:
Treatment
Score: 6.5
OBJECTIVES: This study aimed to evaluate the cost-effectiveness of upadacitinib in patients with moderately to severely active ulcerative colitis (UC…
Upadacitinib as rescue therapy for corticosteroid failure acute severe ulcerati…
PMID: 39934573
Year: 2025
Relationship Type:
Treatment
Score: 6.5
PURPOSE: Acute severe ulcerative colitis (ASUC) is a medical emergent condition, and approximately one-third of patients with ASUC do not respond to …
Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An Inter…
PMID: 39921898
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: There are scarce data available on upadacitinib in children with Crohn's disease (CD). AIM: To evaluate the effectiveness and safety of u…
Insights into adverse events and safety profile of upadacitinib in the manageme…
PMID: 39921836
Year: 2025
Relationship Type:
Adverse Effect
Score: 6.5
BACKGROUND: This systematic review and meta-analysis evaluated the incidence of serious adverse events (SAEs) in patients with Crohn's disease (CD) a…
A Severe Case of Disseminated Herpes Zoster in a Patient With Crohn's Disease o…
PMID: 39886013
Year: 2025
Relationship Type:
Association
Score: 6.5
Herpes zoster (HZ) is caused by the reactivation of the varicella zoster virus and presents with painful vesicular lesions in a dermatomal distributi…
Development and validation of a sensitive LC-MS/MS assay for determination of u…
PMID: 39862900
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor approved by the Food and Drug Administration for the treatment of moderate-to-…
An Analysis of the Effectiveness and Safety of Upadacitinib in the Treatment of…
PMID: 39857773
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Background and Aims: Inflammatory bowel disease (IBD) requires effective treatment options. Upadacitinib, a Janus kinase 1 (JAK1) inhibitor, has show…
Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Pati…
PMID: 39624020
Year: 2025
Relationship Type:
Treatment
Score: 6.5
OBJECTIVE: To assess the development of extramusculoskeletal manifestations (EMMs) among patients with psoriatic arthritis (PsA) or axial spondyloart…
Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An Int…
PMID: 39605286
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are sca…
Persistence, Effectiveness, and Safety of Upadacitinib in Crohn's Disease and U…
PMID: 39588977
Year: 2024
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Real-world data on the effectiveness of upadacitinib for inflammatory bowel disease (IBD) are limited. To assess upadacitinib persisten…
Upadacitinib is associated with clinical response and steroid-free remission fo…
PMID: 39538977
Year: 2025
Relationship Type:
Treatment
Score: 6.5
OBJECTIVE: Upadacitinib, an oral Janus kinase inhibitor (JAKi), is approved for inflammatory bowel disease (IBD) in adults. As on-label use will face…
Successful treatment of Crohn's disease-related peripheral spondyloarthritis wi…
PMID: 39382686
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease (CD), not only causes significant intestinal inflammation but also…
Effectiveness and safety of upadacitinib in acute severe ulcerative colitis pat…
PMID: 39348049
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Upadacitinib is an oral new selective JAK1 inhibitor that has been approved for treating adult patients with moderately to severely active ulcerative…
Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upad…
PMID: 39231444
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: We evaluated the association of achieving endoscopic outcomes at week 12 of induction with improvements in clinical outcomes and quality …
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Bur…
PMID: 39212931
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Endoscopic remission has emerged as an important treatment target in Crohn's disease (CD) and has been associated with improvement in lon…
Upadacitinib for Acute Severe Ulcerative Colitis: A Systematic Review
PMID: 39186564
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Acute severe ulcerative colitis (ASUC) remains a clinical challenge associated with considerable morbidity, including colectomy. Upadacitinib (UPA), …
Rescue therapy with upadacitinib in medically refractory pediatric ulcerative c…
PMID: 38756133
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Approved options for advanced therapy in pediatric inflammatory bowel disease (IBD) are limited. Although Janus kinase (JAK) inhibitors are approved …
Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-t…
PMID: 38712496
Year: 2024
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Janus kinases (JAK) are enzymes involved in signaling pathways that activate the immune system. Upadacitinib, an oral small molecule, i…
Upadacitinib in Crohn's disease
PMID: 38512115
Year: 2024
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: The small molecule and oral selective and reversible Janus kinase (JAK) inhibitor upadacitinib has been approved for the treatment of m…
A Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upad…
PMID: 38306123
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Tumor necrosis factor-alpha inhibitors (TNF-i) are commonly used to treat immune-mediated diseases such as psoriasis, psoriatic arthritis (PsA), infl…